Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus XIFYRM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus XIFYRM.
CHLOROMYXIN vs XIFYRM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
XIFYRM is a monoclonal antibody that targets and neutralizes interleukin-36 (IL-36), thereby inhibiting the inflammatory signaling cascade involved in pustular psoriasis.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
500 mg orally twice daily with food.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life: 15 hours; prolonged in renal impairment (creatinine clearance <30 mL/min) to 30 hours
CHLOROMYXIN is not a recognized drug. No data available.
Renal: 70% unchanged; Fecal: 20%; Biliary: <10%
Category C
Category C
Antibiotic
Antibiotic